Avoro Capital Advisors LLC Purchases Shares of 2,175,000 uniQure (NASDAQ:QURE)

Avoro Capital Advisors LLC bought a new stake in shares of uniQure (NASDAQ:QURE - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,175,000 shares of the biotechnology company's stock, valued at approximately $38,410,000. uniQure comprises 0.5% of Avoro Capital Advisors LLC's holdings, making the stock its 26th biggest position. Avoro Capital Advisors LLC owned 4.46% of uniQure as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Jump Financial LLC raised its holdings in uniQure by 193.5% in the fourth quarter. Jump Financial LLC now owns 211,776 shares of the biotechnology company's stock valued at $3,740,000 after acquiring an additional 139,624 shares in the last quarter. Walleye Capital LLC lifted its position in shares of uniQure by 44.7% during the fourth quarter. Walleye Capital LLC now owns 130,423 shares of the biotechnology company's stock worth $2,303,000 after purchasing an additional 40,281 shares during the last quarter. XTX Topco Ltd bought a new position in shares of uniQure during the fourth quarter worth about $287,000. Quinn Opportunity Partners LLC grew its stake in uniQure by 187.5% in the fourth quarter. Quinn Opportunity Partners LLC now owns 69,000 shares of the biotechnology company's stock worth $1,219,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in uniQure in the fourth quarter valued at about $1,951,000. Institutional investors and hedge funds own 78.83% of the company's stock.

Analyst Upgrades and Downgrades

QURE has been the subject of several research reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. Wells Fargo & Company decreased their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Chardan Capital assumed coverage on shares of uniQure in a research note on Tuesday, April 1st. They set a "buy" rating and a $38.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of uniQure in a research report on Monday, April 21st. Finally, StockNews.com raised shares of uniQure to a "sell" rating in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $38.80.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares of the company's stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares of the company's stock, valued at $2,240,441.70. This represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock worth $961,401 in the last three months. 4.74% of the stock is owned by company insiders.

uniQure Stock Performance

Shares of NASDAQ:QURE traded down $0.08 during trading hours on Friday, hitting $14.18. The stock had a trading volume of 646,241 shares, compared to its average volume of 1,772,228. The stock's fifty day simple moving average is $11.94 and its 200 day simple moving average is $11.54. The firm has a market capitalization of $766.81 million, a price-to-earnings ratio of -2.86 and a beta of 0.42. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.